Douglas Laboratories Multi-Probiotic 15 Billion
Each Multi-Probiotic® 15 Billion Capsule contains beneficial organisms from Lactobacillus and Bifidobacterium genera with additional benefits of prebiotic fructooligosaccharides.
Each serving contains:
Multi-Strain Probiotic Blend - 15 Billion CFU
Lactobacillus acidophilus (DDS®) - 4.3 Billion CFU
Lactobacillus rhamnosus (Lr-32) - 4.3 Billion CFU
Bifidobacterium lactis (HN019) - 1.9 Billion CFU
Lactococcus lactis (Ll-23) - 1.0 Billion CFU
Bifidobacterium longum (Bl-05) - 1.0 Billion CFU
Bifidobacterium bifidum/lactis (Bb-02) - 1.0 Billion CFU
Lactobacillus gasserri (Lg-36) - 1.0 Billion CFU
Streptococcus thermophilus (St-21) - 0.5 Billion CFU
Digestive and Prebiotic Blend - 210 mg
FOS (fructooligosaccharides) and Ulmus fulva (bark)
Other ingredients: Bovine gelatin (capsule), vegetable stearate and silica.
Multi-Probiotic® is a registered mark of Nutri-Health Supplements, LLC, used with permission.
DDS® is a trademark of UAS Laboratories LLC and used under license.
As a dietary supplement, take 1 capsules daily or as directed by your healthcare professional.
Oral supplements of live, beneficial intestinal micro-organisms for nutritional health and well-being are known as probiotics. Probiotic dietary lactobacilli colonize the intestinal tract. Bacteria are continually in competition for colonization space. The original bacterial colonies have an advantage over transient bacteria. Nevertheless, the composition of the intestinal microflora is dynamic and constantly changing. If harmful microorganisms proliferate, the equilibrium is disturbed, and it becomes difficult even for indigenous bacteria to maintain their necessary territory to colonize the intestine. Antibiotics tend to kill off both beneficial and harmful bacteria, and thus may also disturb the normal, healthy balance of intestinal microorganisms.
Various intestinal conditions can compromise the immune system and lower the amounts of healthy intestinal microflora. When potent probiotic supplements, such as Multi-Probiotic 15 Billion, are supplied regularly, chances are greatly increased for establishing and maintaining a healthy population of beneficial intestinal microorganisms. Once established, a normal intestinal microflora rich in lactobacilli creates acidic conditions that are unfavorable for the settlement of pathogenic microorganisms.
Probiotics have been shown to exert a beneficial support through modification of the immune system host via the gut environment. Bifidobacterium lactis HN019 has been clinically shown in research to support the immune system by enhancing the function of leucocytes in adults and the elderly. This strain may also help in the maintenance of bowel regularity and normal GI function. Clinical trials also suggest that the exposure to microbes through the gastrointestinal tract powerfully shapes immune function. In particular, lactobacilli are considered to induce reactions involvingTh1 cells. Research on the L. gasseri strain supplementation has shown a beneficial effect on immunological reactions in school children. Lactobacillus rhamnosus is one of the most widely studied probiotics, noted and valued for its ability to survive in the harsh conditions of the digestive and urinary tracts. L. rhamnosus is extremely well tolerated by men and women with very rare side effects. Studies have shown that, taken regularly, L. rhamnosus can be an effective supplement in promoting and maintaining digestive tract health.
Multi-Probiotic 15 Billion is acid and bile resistant and the cultures undergo a patented cyroprotectant stabilization process for shelf stability. For example, Bifidobacterium was studied in vitro to be extremely resistant to low pH and bile acids in the duodenum. L. acidophilus DDS-1 incorporates proprietary cryoprotectant agents and stabilizers specifically designed to protect the organism and enhance stability. Clinical analysis of DDS-1 and Bifidobacterium also shows increased binding to human intestinal walls and protective effects of intestinal colonization. Certain bacterial acids in the intestines produce secondary bile acids. One study indicated that L. acidophilus DDS-1 decreased the potential for bacterial transformations of primary bile acid.
Prebiotics are carbohydrates that have short molecular chains. They function as non-digestible ingredients that can positively affect selected groups of beneficial intestinal microflora, such as lactobacillus. While probiotics merely add beneficial microflora, prebiotics affect the intestinal environment so that beneficial colonies of microflora can flourish. By aiding the beneficial microflora’s survival, pathogenic microflora can have a decreased chance of survival.